Health
ERS Genomics and Applied StemCell sign agreement on commercialization of CRISPR gene editing tools – News-Medical.net
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of ste…
ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP) co-owned by Dr. Emmanuelle Charpentier, today announced it has signed an agreement with Applied StemCell, Inc., a leading provider of stem cell, animal model, antibody discovery services and reagents.
ERS Genomics holds an exclusive worldwide license from Dr. Charpentier to the foundational patents covering CRISPR/Cas9. Companies can obtain licenses to this technology for in…
-
Noosa News8 hours agoChef Sophie Phipps prepares to open restaurant at 30-acre Alsahwa Estate
-
General23 hours agoAustralian government calls for de-escalation of war in Iran as Coalition endorses US strikes
-
General13 hours agoTony Abbott: ‘Israel is doing the world’s work’
-
Noosa News22 hours agoPhysically present, emotionally checked out: the biggest risk to mental wellbeing